| scholarly article | Q13442814 |
| P2093 | author name string | Gregory S Sawicki | |
| Deborah E Sellers | |||
| Walter M Robinson | |||
| P2860 | cites work | Cystic Fibrosis Adult Care | Q22306058 |
| Predictive 5-year survivorship model of cystic fibrosis | Q30481059 | ||
| Determinants of adherence in adults with cystic fibrosis | Q34616202 | ||
| Patient-reported outcomes in cystic fibrosis | Q36891536 | ||
| Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. | Q36924692 | ||
| Adults with cystic fibrosis report important and unmet needs for disease information | Q40220766 | ||
| Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety | Q42163306 | ||
| So many drugs, so little time: the future challenge of cystic fibrosis care. | Q44278154 | ||
| Mucus clearance and lung function in cystic fibrosis with hypertonic saline | Q46900192 | ||
| Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. | Q50954733 | ||
| Adherence of adult cystic fibrosis patients with airway clearance and exercise regimens | Q80098589 | ||
| Treatment burden and health-related quality of life of children with diabetes, cystic fibrosis and asthma | Q80262318 | ||
| Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? | Q82214146 | ||
| P433 | issue | 2 | |
| P921 | main subject | cystic fibrosis | Q178194 |
| P304 | page(s) | 91-96 | |
| P577 | publication date | 2008-10-26 | |
| P1433 | published in | Journal of Cystic Fibrosis | Q15749341 |
| P1476 | title | High treatment burden in adults with cystic fibrosis: challenges to disease self-management | |
| P478 | volume | 8 |
| Q35671785 | A Cross-Sectional Study of the Psychological Needs of Adults Living with Cystic Fibrosis. |
| Q34979778 | A longitudinal study of the impact of social deprivation and disease severity on employment status in the UK cystic fibrosis population |
| Q90659713 | A systematic literature review of the assessment of treatment burden experienced by patients and their caregivers |
| Q38340909 | A systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis |
| Q36944153 | Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate "normative adherence". |
| Q57603163 | Action planning and coping planning for long-term lifestyle change: theory and assessment |
| Q36913410 | Adherence to airway clearance therapy in pediatric cystic fibrosis: Socioeconomic factors and respiratory outcomes |
| Q90353321 | Adherence to long-term therapies in cystic fibrosis: a French cross-sectional study linking prescribing, dispensing, and hospitalization data |
| Q64075087 | Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework |
| Q39096768 | Adherence to therapies in cystic fibrosis: a targeted literature review. |
| Q36368310 | Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data |
| Q38880490 | An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis. |
| Q30380267 | An exploration of partnership through interactions between young 'expert' patients with cystic fibrosis and healthcare professionals. |
| Q47652015 | An update on new and emerging therapies for cystic fibrosis |
| Q36157341 | Antecedents of self-care in adults with congenital heart defects |
| Q35806994 | Anxiety and depression in adults with cystic fibrosis: a comparison between patients and the general population in Sweden and three other European countries |
| Q59589486 | Assessing the Perceptions of Inspiratory Muscle Training in Children With Cystic Fibrosis and Their Multidisciplinary Team: Mixed-Methods Study |
| Q58758259 | Associations between Flavonoid Intakes and Gut Microbiota in a Group of Adults with Cystic Fibrosis |
| Q37464080 | Associations between genetics, medical status, physical exercise and psychological well-being in adults with cystic fibrosis |
| Q34643645 | Associations between illness perceptions and health-related quality of life in adults with cystic fibrosis |
| Q42973495 | Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis |
| Q37775620 | Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis |
| Q43538692 | Brazilian guidelines for the diagnosis and treatment of cystic fibrosis. |
| Q38975700 | Bronchodilators in cystic fibrosis: a critical analysis |
| Q38845687 | Burden of treatment in the light of the international classification of functioning, disability and health: a "best fit" framework synthesis. |
| Q38996435 | Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor? |
| Q37809636 | Changing epidemiology and clinical issues arising in an ageing cystic fibrosis population |
| Q38186636 | Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis |
| Q47730264 | Coping styles in adults with cystic fibrosis: implications for emotional and social quality of life. |
| Q35558817 | Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. |
| Q51424428 | Cystic Fibrosis: The Dawn of a New Therapeutic Era. |
| Q89219005 | Cystic fibrosis |
| Q37396805 | Cystic fibrosis: addressing the transition from pediatric to adult-oriented health care |
| Q48220142 | Daily pain in adolescents with CF: Effects on adherence, psychological symptoms, and health-related quality of life |
| Q93377708 | Delphi poll to assess consensus on issues influencing long-term adherence to treatments in cystic fibrosis among Italian health care professionals |
| Q38761055 | Development and validation of CF-Medication Beliefs Questionnaire: A mixed-methods approach |
| Q37851986 | Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology |
| Q57688807 | Dornase alfa for cystic fibrosis |
| Q24185927 | Dornase alfa for cystic fibrosis |
| Q40172504 | Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection. |
| Q24624885 | Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation |
| Q59137531 | Effects of high intensity interval training on exercise capacity in people with cystic fibrosis: study protocol for a randomised controlled trial |
| Q36246683 | Effects of treadmill exercise versus Flutter® on respiratory flow and sputum properties in adults with cystic fibrosis: a randomised, controlled, cross-over trial |
| Q84975672 | Employment experiences among adolescents and young adults with cystic fibrosis |
| Q92760185 | Enhancing intrinsic motivation for physical activity among adolescents with cystic fibrosis: a qualitative study of the views of healthcare professionals |
| Q48497804 | Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample |
| Q38683084 | Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008-2012. |
| Q59808844 | Evaluation of Food Insecurity in Adults and Children With Cystic Fibrosis: Community Case Study |
| Q37527159 | Evaluation of Medication-related Self-care Skills in Patients With Cystic Fibrosis |
| Q38025731 | Exercise as part of a cystic fibrosis therapeutic routine |
| Q94266296 | Exercise versus airway clearance techniques for people with cystic fibrosis |
| Q39093026 | Factors affecting nebulised medicine adherence in adult patients with cystic fibrosis: a qualitative study |
| Q38735043 | Factors associated with changes in health-related quality of life in children with cystic fibrosis during 1-year follow-up. |
| Q57072994 | Fatigue in Chronic Respiratory Diseases: Theoretical Framework and Implications For Real-Life Performance and Rehabilitation |
| Q34342709 | Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state |
| Q30300229 | Finalizing a measurement framework for the burden of treatment in complex patients with chronic conditions |
| Q37653062 | Flying the nest: a challenge for young adults with cystic fibrosis and their parents |
| Q38240156 | Gaining the Upper Hand on Pulmonary Drug Delivery |
| Q28066282 | Health Trajectories in People with Cystic Fibrosis in the UK: Exploring the Effect of Social Deprivation |
| Q39853898 | Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis |
| Q92958587 | Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy |
| Q58111269 | Identifying and Integrating Parent Priorities for Psychosocial Support Services in a Pediatric Cystic Fibrosis Clinic |
| Q40505534 | Inhalation of tobramycin using simulated cystic fibrosis patient profiles |
| Q50051514 | Inhaled mannitol for cystic fibrosis |
| Q24186558 | Inhaled mannitol for cystic fibrosis |
| Q92514388 | Inspiration for the Future: The Role of Inspiratory Muscle Training in Cystic Fibrosis |
| Q26785374 | International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety |
| Q94398225 | Interventions for improving adherence to treatment in cystic fibrosis |
| Q24186754 | Interventions for improving adherence to treatment in cystic fibrosis |
| Q53826586 | Living with cystic fibrosis - a qualitative study of a life coaching intervention. |
| Q22305306 | Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry |
| Q43454338 | Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis |
| Q35640326 | Longitudinal impact of demographic and clinical variables on health-related quality of life in cystic fibrosis. |
| Q36295243 | Longitudinal sampling of the lung microbiota in individuals with cystic fibrosis |
| Q37141462 | Longitudinal trends in health-related quality of life in adults with cystic fibrosis |
| Q90049406 | Lung transplant referral practice patterns: a survey of cystic fibrosis physicians and general pulmonologists |
| Q33697276 | Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy |
| Q36154317 | Measuring the transition readiness of youth with special healthcare needs: validation of the TRAQ--Transition Readiness Assessment Questionnaire |
| Q35955792 | Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis |
| Q34161094 | Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives |
| Q89584815 | Nebuliser cleaning and disinfection practice in the home among patients with cystic fibrosis |
| Q24197879 | Nebuliser systems for drug delivery in cystic fibrosis |
| Q38532426 | New and Emerging Treatments for Cystic Fibrosis |
| Q38829727 | Objective Measurement of Adherence to Out-Patient Airway Clearance Therapy by High-Frequency Chest Wall Compression in Cystic Fibrosis. |
| Q35118399 | Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus |
| Q55626447 | Parents as equal partners in the paediatric cystic fibrosis multidisciplinary team. |
| Q64229716 | Patient experience after kidney transplant: a conceptual framework of treatment burden |
| Q40540630 | Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report |
| Q42220314 | Patient-perceived treatment burden of chronic obstructive pulmonary disease. |
| Q37576913 | Perception of first respiratory infection with Pseudomonas aeruginosa by people with cystic fibrosis and those close to them: an online qualitative study |
| Q40852320 | Pharmacists' perspectives on monitoring adherence to treatment in Cystic Fibrosis |
| Q47266208 | Pharmacological management of cystic fibrosis related diabetes |
| Q47870347 | Physical activity participation by adults with cystic fibrosis: An observational study. |
| Q41907045 | Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients. |
| Q41119815 | Preferences and Stated Adherence for Antibiotic Treatment of Cystic Fibrosis Pseudomonas Infections |
| Q40164055 | Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres |
| Q33824149 | Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment |
| Q44721568 | Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample |
| Q40093588 | Pulmonary Pharmacokinetics of Colistin Following Administration of Dry Powder Aerosols in Rats. |
| Q44687612 | Regimen complexity and prescription adherence in dialysis patients. |
| Q47692517 | Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. |
| Q55017302 | Resource Use Evaluation of Tobramycin Formulations in a State Medicaid Program. |
| Q36677316 | Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study |
| Q33861117 | Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial |
| Q46141297 | Seeing is Engaging: Vlogs as a Tool for Patient Engagement |
| Q48503902 | Self-management for bronchiectasis. |
| Q91709600 | Sildenafil improves exercise capacity in patients with cystic fibrosis: a proof-of-concept clinical trial |
| Q28066704 | Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis |
| Q33565133 | Strengthening care teams to improve adherence in cystic fibrosis: a qualitative practice assessment and quality improvement initiative |
| Q36034488 | Tackling the increasing complexity of CF care |
| Q83156270 | Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis |
| Q94674631 | The Cystic Fibrosis Impact Questionnaire: qualitative development and cognitive evaluation of a new patient-reported outcome instrument to assess the life impacts of cystic fibrosis |
| Q33550523 | The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation |
| Q33644835 | The effects of inhaled aztreonam on the cystic fibrosis lung microbiome. |
| Q33744569 | The impact of medication adherence on lung health outcomes in cystic fibrosis |
| Q38962747 | Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis |
| Q26829604 | Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis |
| Q37940005 | Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis |
| Q38630919 | Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis |
| Q39282311 | Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence |
| Q38160206 | Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis |
| Q38358856 | Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis |
| Q46785710 | Trajectories of caregiver burden in families of adult cystic fibrosis patients |
| Q38390841 | Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research? |
| Q33877099 | Treatment adherence and health outcomes in patients with bronchiectasis |
| Q33815570 | Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. |
| Q37381499 | Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder |
| Q33441914 | User Preferences and Design Recommendations for an mHealth App to Promote Cystic Fibrosis Self-Management |
| Q38160400 | Young adult palliative care: challenges and opportunities |
Search more.